Lone Pine Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Lone Pine Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-260,985	Closed	-$45.1M	–	62
2015 Q1	$45.1M	Sell	260,985 -1,622,669	-86%	-$278M	0.17%	53
2014 Q4	$308M	Buy	1,883,654 +95,047	+5%	+$15.8M	1.29%	25
2014 Q3	$287M	Sell	1,788,607 -298,520	-14%	-$45.9M	1.12%	34
2014 Q2	$307M	Sell	2,087,127 -257,359	-11%	-$35.7M	1.24%	28
2014 Q1	$325M	Buy	+2,344,486	New	+$353M	1.41%	27

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

WBC

Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Lone Pine Capital's JAZZ Position: Q2 2015 in Review

Lone Pine Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2015, closing a stake of 260,985 shares — an estimated $45.1M sold.

Lone Pine Capital first reported a position in JAZZ in Q1 2014 and held it in 5 quarters. The position peaked at $325M in Q1 2014. 373 funds tracked by Wall St. Rank hold JAZZ as of Q2 2015.

Lone Pine Capital reported no remaining Jazz Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Lone Pine Capital sold 260,985 Jazz Pharmaceuticals shares in Q2 2015, an estimated $45.1M.
Lone Pine Capital first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Lone Pine Capital's Jazz Pharmaceuticals position peaked at $325M in Q1 2014.
373 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2015.

Based on Lone Pine Capital's 13F filing for Q2 2015, filed 14 Aug 2015.